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ABSTRACT
Objective The aim of this study was to assess long-term 
golimumab therapy in patients with rheumatoid arthritis 
(RA) who discontinued previous tumour necrosis factor 
alpha (TNFα) inhibitor(s) for any reason.
Methods Results through week 24 of this multicentre, 
randomised, double-blind, placebo-controlled study 
of active RA (≥4 tender, ≥4 swollen joints) were 
previously reported. Patients received placebo (Group 
1), 50 mg golimumab (Group 2) or 100 mg golimumab 
(Group 3) subcutaneous injections every 4 weeks. 
Patients from Groups 1 and 2 with <20% improvement 
in tender/swollen joints at week 16 early escaped to 
golimumab 50 mg and 100 mg, respectively. At week 
24, Group 1 patients crossed over to golimumab 50 mg, 
Group 2 continued golimumab 50/100 mg per escape 
status and Group 3 maintained dosing. Data through 
week 160 are reported.
Results 459 of the 461 randomised patients were 
treated; 236/459 (51%) continued treatment through 
week 160. From week 24 to week 100, ACR20 (≥20% 
improvement in American College of Rheumatology 
criteria) response and ≥0.25 unit HAQ (Health 
Assessment Questionnaire) improvement were sustained 
in 70–73% and 75–81% of responding patients, 
respectively. Overall at week 160, 63%, 67% and 57% of 
patients achieved ACR20 response and 59%, 65% and 
64% had HAQ improvement ≥0.25 unit in Groups 1, 2 and 
3, respectively. Adjusted for follow-up duration, adverse 
event incidences (95% CI) per 100 patient-years among 
patients treated with golimumab 50 mg and 100 mg were 
4.70 (2.63 to 7.75) and 8.07 (6.02 to 10.58) for serious 
infection, 0.95 (0.20 to 2.77) and 2.04 (1.09 to 3.49) for 
malignancy and 0.00 (0.00 to 0.94) and 0.62 (0.17 to 
1.59) for death, respectively.
Conclusion In patients with active RA who 
discontinued previous TNF-antagonist treatment, 
golimumab 50 and 100 mg injections every 4 weeks 
yielded sustained improvements in signs/symptoms 
and physical function in ~57–67% of patients who 
continued treatment. Golimumab safety was consistent 
with other anti-TNF agents, although defi nitive 
conclusions regarding long-term safety require further 
monitoring.
EXTENDED REPORT
Golimumab in patients with active rheumatoid arthritis 
who have previous experience with tumour necrosis 
factor inhibitors: results of a long-term extension of 
the randomised, double-blind, placebo-controlled 
GO-AFTER study through week 160
Josef S Smolen,1 Jonathan Kay,2 Robert B M Landewé,3 Eric L Matteson,4 
Norman Gaylis,5 Jurgen Wollenhaupt,6 Frederick T Murphy,7 Yiying Zhou,8 
Elizabeth C Hsia,9,10 Mittie K Doyle9,10
Tumour necrosis factor alpha (TNFα) inhibitors 
have been used to treat rheumatoid arthritis (RA) 
for >10 years. Patients with insufﬁ cient response 
to TNF inhibitors are routinely switched to other 
biological agents, including other TNF inhibitors. 
Thus, increasingly more patients with RA have 
previous experience with ≥1 TNF inhibitor. Among 
the newer anti-TNF agents, golimumab is a human 
monoclonal anti-TNF agent administered subcuta-
neously every 4 weeks.
GO-AFTER (GOlimumab After Former anti-
tumour necrosis factor α Therapy Evaluated in 
Rheumatoid arthritis) was the ﬁ rst prospective, 
randomised, phase 3, double-blind, placebo-con-
trolled trial to assess a TNF inhibitor in patients 
with active RA who previously received TNF 
inhibitor(s). These patients had also received 
several disease-modifying antirheumatic drugs 
(DMARDs) prior to TNF inhibitor(s), thereby 
representing a difﬁ cult-to-treat population. 
Treatment with golimumab 50 mg and 100 mg 
every 4 weeks versus placebo yielded signiﬁ cantly 
higher ACR20 (≥20% improvement in American 
College of Rheumatology criteria) response rates 
at week 14 (35% and 38% vs 18%, respectively; 
both p<0.001) and no unexpected safety concerns 
through week 24.1 Efﬁ cacy and safety ﬁ ndings 
through week 160 of the GO-AFTER long-term 
extension (LTE) are reported herein.
PATIENTS AND METHODS
GO-AFTER (NCT00299546) was conducted 
according to the Declaration of Helsinki. All patients 
provided written informed consent, and the proto-
col was approved by each institution’s human sub-
jects ethical review board.
Patients
Patient enrolment began 21 February 2006; data 
were collected at visits conducted through LTE 
week 160. Eligible patients with RA2 had active dis-
ease (≥4 swollen, ≥4 tender joints); had previously 
received etanercept, adalimumab or inﬂ iximab for 
≥8 (adalimumab, etanercept) or ≥12 (inﬂ iximab) 
annrheumdis-2011-200956.indd   1 7/11/2012   7:15:17 PM
Ann Rheum Dis 2012;71:1671–1679. doi:10.1136/annrheumdis-2011-200956 1671
annrheumdis-2011-200956)
(http://dx.doi.org/10.1136/
Clinical and epidemiological research
criteria.4–6 DAS28 scores were determined using erythrocyte 
sedimentation rate (ESR) and C reactive protein (CRP) with 
established cut points for disease activity states.7 Clinical remis-
sion according to ACR–EULAR (European League Against 
Rheumatism) criteria was also evaluated using the Simpliﬁ ed 
Disease Activity Index (SDAI score≤3.3).8 9 Physical function was 
assessed using the Health Assessment Questionnaire (HAQ).10 
Adverse events (AEs) were coded according to MedDRA.1
Data analysis
Clinical outcomes through week 160 are summarised as 
observed data by randomised treatment groups using descrip-
tive statistics; missing data were neither replaced nor imputed. 
All patients remaining in the study, including those initially 
treated with placebo, received golimumab for ≥2 years by week 
160, precluding statistical comparisons among treatment groups. 
The proportions of patients achieving ACR response, DAS28 
response/remission, ACR-EULAR index remission (SDAI) 
remission and/or ≥0.25 unit improvement in HAQ11 were deter-
mined. Changes from baseline (week 0 of main study) were 
also determined. Treatment groups were deﬁ ned according to 
patients’ original randomisation: (1) patients randomised to pla-
cebo, including patients who EE at week 16 or crossed over at 
week 24 to golimumab 50 mg and/or escalated after week 24 to 
100 mg; (2) patients randomised to golimumab 50 mg, includ-
ing patients who EE at week 16 or dose escalated after week 
24 to 100 mg; and (3) patients randomised to golimumab 100 
mg. Efﬁ cacy data from one North American site (16 patients) 
were excluded because of protocol violations identiﬁ ed during 
weeks; and could have discontinued these agents for any reason 
(documented as lack of efﬁ cacy, intolerance, other). Additional 
inclusion/exclusion criteria were previously reported.1
Study design
Patients were randomised (1:1:1) to receive subcutaneous injec-
tions of placebo, golimumab 50 mg or golimumab 100 mg every 
4 weeks. Stable doses of synthetic DMARDs were allowed. 
Patients and investigators were blinded to treatment assign-
ment; golimumab and placebo were supplied in identical single-
use vials.
Patients in the placebo and golimumab 50 mg groups with 
<20% improvement in both tender and swollen joint counts 
at week 16 early escaped (EE) to receive golimumab 50 mg or 
100 mg, respectively, at week 16 and week 20. Dosing was not 
changed in the 100 mg group.
GO-AFTER included a LTE. From week 24 forward, patients 
in the placebo group crossed over to golimumab 50 mg every 
4 weeks and patients in the golimumab 50 mg group contin-
ued with golimumab 50 or 100 mg every 4 weeks per EE status. 
The study blind was maintained during the LTE until the week 
24 database lock, after which patients receiving golimumab 50 
mg could escalate to 100 mg at the investigator’s discretion. 
Golimumab doses could not be reduced through week 160.
Procedures
Clinical response through week 160 was assessed using 
ACR20/50/70,3 28-joint count Disease Activity Score (DAS28) 
response (good/moderate) and DAS28 remission (score<2.6) 
Figure 1 Patient disposition through week 160.
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standard auditing; baseline and safety data from these patients 
were included. Because numbers of patients in LTE phases of 
double-blind trials typically decline over time, thereby yielding 
falsely elevated response rates among the remaining responder-
enriched population,12 efﬁ cacy data are presented as (1) abso-
lute numbers to demonstrate actual changes observed during 
the LTE, despite the limited numbers of patients with response 
data, and (2) proportions of responders based on randomised 
patients who continued study participation and had response 
data, despite the enriched nature of the resulting population.
Safety data are summarised for randomised and treated 
patients. Individual AEs were attributed to treatment received at 
onset; therefore, individual patients may appear in >1 treatment 
column. Standardised incidence ratios (SIRs) for malignancies 
were determined using the Surveillance, Epidemiology and End 
Results (SEER) database.13
RESULTS
Patient disposition and characteristics
Patient recruitment began in February 2006, and data included 
in this report were collected through study week 160. Patient 
disposition through week 24 has been detailed. Overall, 57 
of 461 (12.4%) randomised patients discontinued study par-
ticipation through week 24, including 31/155 (20.0%), 12/153 
(7.8%) and 14/153 (9.2%) patients randomised to receive pla-
cebo, golimumab 50 mg and golimumab 100 mg, respectively.1 
Approximately one-half of treated patients continued study 
treatment through week 160 (ﬁ gure 1). Common reasons for 
study agent discontinuation included unsatisfactory therapeutic 
effect (43% of discontinued patients) and AEs (28%, including 
nine patients with worsening RA) (ﬁ gure 1). The proportions of 
patients discontinuing study agent due to AEs or unsatisfactory 
therapeutic effect increased with greater number of previous 
TNF antagonists (table 1).
The extent of active disease, inﬂ ammation and physical func-
tion impairment and reasons for previous TNF inhibitor(s) dis-
continuation were consistent across treatment groups (table 1). 
Overall, 178 patients dose escalated (50→100 mg) at the inves-
tigator’s discretion. During the LTE, 70% (137/195) of eligible 
patients dose escalated (ﬁ gure 1).
Clinical response
The proportions of patients achieving ACR20, DAS28-ESR 
response and DAS28-ESR remission at week 24 among patients 
Table 1 Summary of patient characteristics and RA medications at baseline of the GO-AFTER trial
 Placebo* Golimumab 50 mg† Golimumab 100 mg
Number of randomised patients 155 153 153
Female 132 (85.2%) 113 (73.9%) 122 (79.7%)
Age 54.8±13.07 (54.0) 53.9±11.47 (55.0) 53.7±12.26 (55.0)
Disease duration (years) 12.4±9.58 (9.8) 12.4±9.24 (9.6) 10.6±7.90 (8.7)
CRP (mg/dl) 2.1±3.16 (1.0) 2.2±2.97 (0.8) 2.1±3.38 (0.8)
ESR (mm/h) 38.4±26.27 (32.0) 35.2±26.98 (27.5) 37.9±29.92 (30.0)
Number of swollen joints (0–66) 17.5±11.76 (14.0) 17.8±11.82 (14.0) 15.4±9.49 (13.0)
Number of tender joints (0–68) 30.0±17.56 (26.0) 30.6±16.86 (27.0) 29.1±16.69 (26.0)
HAQ score (0–3) 1.6±0.6 (1.8) 1.6±0.7 (1.60) 1.5±0.6 (1.5)
DAS28-ESR score (0–10) 6.2±1.19 (6.3) 6.3±1.25 (6.3) 6.1±1.24 (6.1)
DAS28-CRP score (0–10) 5.1±0.99 (5.1) 5.3±1.05 (5.4) 5.1±0.92 (5.1)
SDAI score (0–100) 40.9±14.59 (38.4) 43.2±15.89 (42.1) 40.7±13.88 (40.3)
Previous anti-TNF for RA 155 (100.0%) 153 (100.0%) 153 (100.0%)
Adalimumab, by reason for d/c  85 (54.8%)  72 (47.1%)  65 (42.5%)
 Lack of effi cacy  53 (34.2%)  44 (28.8%)  40 (26.1%)
 Intolerance   3 (1.9%)   9 (5.9%)  10 (6.5%)
 Other  29 (18.7%)  19 (12.4%)  15 (9.8%)
Etanercept, by reason for d/c  73 (47.1%)  76 (49.7%)  73 (47.7%)
 Lack of effi cacy  40 (25.8%)  49 (32.0%)  40 (26.1%)
 Intolerance  11 (7.1%)   4 (2.6%)  10 (6.5%)
 Other  22 (14.2%)  23 (15.0%)  23 (15.0%)
Infl iximab, by reason for d/c  83 (53.5%)  64 (41.8%)  71 (46.4%)
 Lack of effi cacy  48 (31.0%)  33 (21.6%)  36 (23.5%)
 Intolerance  14 (9.0%)   9 (5.9%)  16 (10.5%)
 Other  21 (13.5%)  22 (14.4%)  19 (12.4%)
Methotrexate use at baseline 102 (65.8%) 103 (67.8%) 100 (65.8%)
Number of previous anti-TNF agents‡
 1 previous anti-TNF (n=292) 2 previous anti-TNFs (n=113) 3 previous anti-TNFs (n=40)
Reason for d/c through week 160
 AE  34 (11.6%)  18 (15.9%)  11 (27.5%)
 Death   3 (1.0%)   0 (0.0%)   0 (0.0%)
 Lost to follow-up   5 (1.7%)   2 (1.8%)   0 (0.0%)
 Other  33 (11.3%)   9 (8.0%)   2 (5.0%)
 Unsatisfactory therapeutic effect  48 (16.4%)  29 (25.7%)  15 (37.5%)
Data presented are mean ±SD (median) or number (%) of randomised patients.
*Includes patients who EE at week 16 or crossed over at week 24 to receive golimumab 50 mg or dose escalated after the week 24 database lock to receive golimumab 100 mg.
†Includes patients who EE at week 16 or dose escalated after the week 24 database lock to receive golimumab 100 mg.
‡Based on the 445 patients included in effi cacy analyses after exclusion of 16 patients at one study site.
AE, adverse event; CRP, C reactive protein; DAS, Disease Activity Score; d/c, discontinuation; EE, early escaped; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment 
Questionnaire; RA, rheumatoid arthritis; SDAI, Simplifi ed Disease Activity Index; TNF, tumour necrosis factor.
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Table 2 Summary of clinical response to golimumab at weeks 52, 100 and 160 of the GO-AFTER trial
 Placebo* Golimumab 50 mg† Golimumab 100 mg
Number of randomised patients 150 147 148
Golimumab-treated patients with ACR response data at:
 Weeks 52 and 100 150 147 148
 Week 160‡  75  81  81
ACR20 response
 Week 52  58/150 (38.7%)  59/147 (40.1%)  77/148 (52.0%)
 Week 100  57/150 (38.0%)  64/147 (43.5%)  66/148 (44.6%)
 Week 160  47/75 (62.7%)  54/81 (66.7%)  46/81 (56.8%)
ACR50 response
 Week 52  32/150 (21.3%)  27/147 (18.4%)  35/148 (23.6%)
 Week 100  36/150 (24.0%)  36/147 (24.5%)  37/148 (25.0%)
 Week 160  25/75 (33.3%)  36/81 (44.4%)  29/81 (35.8%)
ACR70 response
 Week 52  11/150 (7.3%)  10/147 (6.8%)  17/148 (11.5%)
 Week 100  14/150 (9.3%)  18/147 (12.2%)  20/148 (13.5%)
 Week 160  13/75 (17.3%)  12/81 (14.8%)  19/81 (23.5%)
DAS28-ESR§ response (good/moderate)¶
 Week 52  73/106 (68.9%)  78/113 (69.0%)  78/108 (72.2%)
 Week 100  70/89 (78.7%)  77/95 (81.1%)  79/102 (77.5%)
 Week 160  51/71 (71.8%)  67/80 (83.8%)  55/77 (71.4%)
DAS28-ESR§ remission (<2.6)¶
 Week 52  9/106 (8.5%)  16/114 (14.0%)  24/109 (22.0%)
 Week 100  15/89 (16.9%)  15/96 (15.6%)  23/104 (22.1%)
 Week 160  12/71 (16.9%)  10/80 (12.5%)  17/79 (21.5%)
DAS28-CRP response (good/moderate)  
 Week 52  72/150 (48.0%)  80/147 (54.4%)  94/148 (63.5%)
 Week 100  71/150 (47.3%)  79/147 (53.7%)  87/148 (58.8%)
 Week 160¶  54/70 (77.1%)  66/80 (82.5%)  61/77 (79.2%)
DAS28-CRP <3.2¶  
 Week 52  30/104 (28.8%)  33/115 (28.7%)  39/107 (36.4%)
 Week 100  43/87 (49.4%)  37/96 (38.5%)  43/100 (43.0%)
 Week 160  30/70 (42.9%)  32/80 (40.0%)  35/78 (44.9%)
DAS28-CRP remission (<2.6)
 Week 52  12/150 (8.0%)  13/147 (8.8%)  27/148 (18.2%)
 Week 100  20/150 (13.3%)  21/147 (14.3%)  27/148 (18.2%)
 Week 160¶  16/70 (22.9%)  22/80 (27.5%)  21/78 (26.9%)
SDAI remission (≤3.3)¶
 Week 52   6/104 (5.8%)   9/115 (7.8%)  14/107 (13.1%)
 Week 100   8/87 (9.2%)  11/96 (11.5%)  15/100 (15.0%)
 Week 160   8/70 (11.4%)   7/80 (8.8%)  18/78 (23.1%)
SDAI score >3.3 and <11 (low disease activity)¶
 Week 52  23/104 (22.1%)  23/115 (20.0%)  25/107 (23.4%)
 Week 100  38/87 (43.7%)  26/96 (27.1%)  28/100 (28.0%)
 Week 160  24/70 (34.3%)  23/80 (28.8%)  20/78 (25.6%)
SDAI score ≥11 and <26 (moderate disease activity)¶
 Week 52  42/104 (40.4%)  49/115 (42.6%)  40/107 (37.4%)
 Week 100  22/87 (25.3%)  31/96 (32.3%)  33/100 (33.0%)
 Week 160  23/70 (32.9%)  35/80 (43.8%)  25/78 (32.1%)
SDAI score ≥26 (severe disease activity)¶
 Week 52  33/104 (31.7%)  34/115 (29.6%)  28/107 (26.2%)
 Week 100  19/87 (21.8%)  28/96 (29.2%)  24/100 (24.0%)
 Week 160  15/70 (21.4%)  15/80 (18.8%)  15/78 (19.2%)
HAQ improvement ≥0.25¶
 Week 52  58/108 (53.7%)  65/116 (56.0%)  74/116 (63.8%)
 Week 100  51/92 (55.4%)  59/97 (60.8%)  62/104 (59.6%)
 Week 160  44/75 (58.7%)  53/81 (65.4%)  51/80 (63.8%)
Data presented are median (interquartile range) or number (%) of randomised patients. Effi cacy data pertaining to 16 patients (5, 6 and 5 patients randomised to placebo, golimumab 50 
mg and golimumab 100 mg, respectively) at site 7465 were excluded due to violations at the study site identifi ed during the sponsor’s standard audit processes.
*Includes patients who EE at week 16 or crossed over at week 24 to receive golimumab 50 mg or dose escalated after the week 24 database lock to receive golimumab 100 mg.
†Includes patients who EE at week 16 or dose escalated after the week 24 database lock to receive golimumab 100 mg.
‡By week 160, only 75, 81 and 81 patients had ACR response data in Groups 1, 2 and 3, respectively.
§ESR determinations were not available for all patients at all time points; therefore, DAS28-ESR scores were determined in fewer patients.
¶Analysis based on observed data.
ACR, American College of Rheumatology; CRP, C reactive protein; DAS, Disease Activity Score; EE, early escaped; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment 
Questionnaire; SDAI, Simplifi ed Disease Activity Index.
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who received golimumab 50 mg (34%, 46% and 10%, respec-
tively) and 100 mg (44%, 61% and 16%, respectively) were sig-
niﬁ cantly higher versus placebo-treated patients (17%, 25% and 
3%, respectively; all p<0.05).1
The proportions of patients meeting the more stringent 
ACR50/70 response criteria appeared stable from week 52 to 
week 160 in all treatment groups (table 2). Similar ﬁ ndings were 
generally observed in ≥1 golimumab group(s) for DAS28-ESR 
response, SDAI low disease activity (>3.3–11), SDAI remission 
and HAQ improvement (table 2). Thus, despite smaller numbers 
of patients in each group over time, response rates were gener-
ally sustained.
An important aspect of managing difﬁ cult-to-treat RA relates 
to maintenance of response. From week 24 to week 100, 
ACR20, DAS28 and ≥0.25 unit HAQ responses were sustained 
in 70–73%, 78–84% and 75–81% of responding patients, respec-
tively (table 3).
Among the 137 patients who dose escalated from 50 mg to 
100 mg through week 160 (ﬁ gure 1), within 12 weeks follow-
ing dose escalation, ACR20 and ACR50 response rates increased 
and were generally maintained over the subsequent 88 weeks. A 
similar pattern was observed for DAS28 responses (table 3).
Golimumab efﬁ cacy was conﬁ rmed in patients receiving 
placebo→golimumab 50 mg with or without further escalation 
to 100 mg. Clinical and functional response rates were similar to 
those demonstrated by patients who received golimumab since 
week 0 (tables 2 and 3).
Adverse events
AEs through week 24 of GO-AFTER have been reported.1 During 
the double-blind, placebo-controlled phase (weeks 0–16), 70%, 
61% and 73% of placebo, golimumab 50 mg and golimumab 100 
mg patients, respectively, experienced AEs. Infections (28%, 27% 
and 25%), serious AEs (7%, 5% and 3%) and serious infections 
(2%, 2% and 1%) were also consistent across treatment groups. 
More patients receiving golimumab 100 mg (11%) had injection-
site reactions versus placebo (3%) or golimumab 50 mg (4%).1
 Largely because the GO-AFTER study design encompassed 
early escape and crossover to golimumab, average weeks of fol-
low-up for LTE patients receiving golimumab 50 mg and 100 mg 
were 32 and 36 weeks at week 52, 48 and 65 weeks at week 100 
and 60 and 102 weeks at week 160, respectively (table 4). Total 
patient-years of follow-up were 58, 319 and 645, respectively, 
for placebo, golimumab 50 mg and golimumab 100 mg.
Table 3 Sustained clinical response to golimumab in the GO-AFTER trial
 Placebo* Golimumab 50 mg†
Golimumab 100 
mg
Number of randomised patients 150 147 148
Golimumab-treated patients with response data at:
 Weeks 52 and 100 150 147 148
 Week 160‡ 75 81 81
ACR20 response at both week 24 and week 100§¶ 38/54 (70.4%) 40/55 (72.7%)
ACR20 response relative to dose escalation (50→100 mg) 
among patients with ample data¶
 Previous to dose escalation 43/117 (36.8%)
 12 weeks after dose escalation 48/100 (48.0%)
 24 weeks after dose escalation 36/69 (52.2%)
ACR50 response at both week 24 and week 100§¶ 20/25 (80.0%) 15/26 (57.7%)
ACR50 response relative to dose escalation (50→100 mg) 
among patients with ample data¶
 Previous to dose escalation 9/117 (7.7%)
 12 weeks after dose escalation 21/100 (21.0%)
 24 weeks after dose escalation 18/69 (26.1%)
ACR70 response at both week 24 and week 100 10/14 (71.4%) 6/11 (54.5%)
DAS28-ESR** response at both week 24 and week 100 55/67 (82.1%) 63/77 (81.8%)
DAS28-ESR** response relative to dose escalation 
(50→100 mg) among patients with ample data¶
 Previous to dose escalation 17/35 (48.6%)
 12 weeks after dose escalation 19/30 (63.3%)
 24 weeks after dose escalation 21/29 (72.4%)
DAS28-CRP response at both week 24 and week 100 55/71 (77.5%) 62/74 (83.8%)
DAS28-CRP response relative to dose escalation 
(50→100 mg) among patients with ample data¶
 Previous to dose escalation 63/113 (55.8%)
 12 weeks after dose escalation 65/98 (66.3%)
 24 weeks after dose escalation 46/66 (69.7%)
HAQ improvement ≥0.25 at both week 24 and week 100¶  55/68 (80.9%) 55/73 (75.3%)
Data presented are median (interquartile range) or number (%) of randomised patients with suffi cient data. Effi cacy data pertaining to 
16 patients (5, 6 and 5 patients randomised to placebo, golimumab 50 mg and golimumab 100 mg, respectively) at site 7465 were 
excluded due to violations at the study site identifi ed during the sponsor’s standard audit processes.
*Includes patients who EE at week 16 or crossed over at week 24 to receive golimumab 50 mg or dose escalated after the week 24 
database lock to receive golimumab 100 mg.
†Includes patients who EE at week 16 or dose escalated after the week 24 database lock to receive golimumab 100 mg.
‡By week 160, only 75, 81 and 81 patients had ACR response data in the placebo, golimumab 50 mg and golimumab 100 mg groups.
§Based on the week 24 responders who remained in the trial at week 100 for response rates at weeks 52, 100 and 160, respectively.
¶Analysis based on observed data.
**ESR determinations were not available for all patients at all time points; therefore, DAS28-ESR scores were determined in fewer patients.
ACR, American College of Rheumatology; CRP, C reactive protein; DAS, Disease Activity Score; EE, early escaped; ESR, erythrocyte 
sedimentation rate; HAQ, Health Assessment Questionnaire.
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Through week 52, when average weeks of follow-up were 
comparable for 50 mg and 100 mg, 76% of patients in each 
group experienced ≥1 AE, indicating no dose response. By week 
160, 81% (50 mg) and 90% (100 mg) of patients experienced ≥1 
AE; respective incidences were 18% and 25% for serious AEs, 
9% and 12% for discontinuation of study agent due to an AE 
and 5% and 9% for serious infections (table 4).
At week 160, the incidences (95% CI) of serious infection were 
8.66 (2.81 to 20.22), 4.70 (2.63 to 7.75) and 8.07 (6.02 to 10.58) 
per 100 patient-years (/100pt-years) of follow-up in patients 
randomised to placebo, golimumab 50 mg and golimumab 100 
mg, respectively. For patients treated with golimumab 50 mg, 
the incidence/100pt-years (95% CI) of serious infections was 
not increased at week 52 (5.78 (2.77 to 10.63)) or week 100 
(5.79 (3.24 to 9.95)) but was increased for golimumab 100 mg at 
week 160 (8.07) relative to week 52 (6.10) and week 100 (6.63). 
However, the 95% CI at week 100 (4.33 to 9.72) and week 160 
(6.02 to 10.58) was contained within that for week 52 (3.05 to 
10.92) (table 4). In the golimumab 100 mg group, one patient 
had histoplasmosis and another had pulmonary tuberculosis. 
Further details of these opportunistic infections are provided in 
the online supplement.
The incidences (95% CI) of death through week 160 
were 1.73 (0.04 to 9.65), 0.00 (0.00 to 0.94) and 0.62 (0.17 to 
1.59)/100pt-years, respectively, for placebo, golimumab 50 mg 
and golimumab 100 mg (table 4). As reported previously,1 one 
placebo-treated patient died 6 months after enrolment. This 
80-year-old woman who did not EE and never received goli-
mumab died from pancreatic cancer on day 177. Four additional 
patients, all women who received golimumab 100 mg, died 
between weeks 100 and 160. The reported causes (and times) 
of death were aggressive lymphoma (week 132), cardiovascular 
event (week 141), congestive heart failure (week 146) and pneu-
monia (week 158). Further details of patient deaths are provided 
in the online supplement.
The incidences (95% CI) of malignancy at week 160 were 1.73 
(0.04 to 9.66), 0.95 (0.20 to 2.77) and 2.04 (1.09 to 3.49)/100pt-
years for placebo, golimumab 50 mg and golimumab 100 mg, 
respectively. The largest difference between groups was observed 
for lymphoma, with incidences (95% CI) of 0.00 (0.00 to 0.94) 
for golimumab 50 mg and 0.62 (0.17 to 1.59) for golimumab 100 
mg (table 4). Among patients who received golimumab 100 mg, 
although the incidence (95% CI) of malignancy/100pt-years 
was not increased from week 52 (1.12 (0.14 to 4.03)) to week 
100 (0.77 (0.16 to 2.24)), it was higher at week 160 (2.04 (1.09 
to 3.49)).
In an analysis comparing malignancy incidences with expected 
rates in the general US population per the SEER database (table 
5), the 95% CI of SIRs for all treatment groups included unity. 
Thus, the incidence of all malignancies occurring among patients 
treated in this study does not differ signiﬁ cantly from those 
expected in the general US population. However, the 95% CI of 
the SIR for lymphoma in the golimumab 100 mg group (5.55 to 
52.15) did not include unity, suggesting that the lymphoma risk 
is increased with golimumab 100 mg (table 5).
DISCUSSION
We previously reported on the use of subcutaneous golimumab 
in 461 patients with active RA who have previous experience 
with TNF antagonists in GO-AFTER, the ﬁ rst prospective, ran-
domised, double-blind, placebo-controlled trial conducted in this 
patient population and the only such study with efﬁ cacy analy-
sed according to randomised treatment groups. GO-AFTER has 
the longest planned follow-up period (5 years) among studies 
involving similar patient populations. Through week 24, goli-
mumab 50 mg and 100 mg every 4 weeks yielded statistically 
signiﬁ cantly higher proportions of patients achieving clinical 
response and clinically meaningful improvements in physical 
function versus placebo and no unexpected safety concerns.1
The GO-AFTER LTE that began at week 24 is ongoing; we 
now report ﬁ ndings through week 160, during which patients 
randomised to placebo crossed over to golimumab 50 mg and 
then all patients receiving golimumab 50 mg could have esca-
lated from 50 mg to 100 mg. Patients randomised to golimumab 
100 mg did not change treatment. Although comparative efﬁ -
cacy of golimumab 50 mg and 100 mg was similar at week 14, 
the golimumab dose was increased for 70% of eligible patients 
during the LTE, likely reﬂ ecting the refractory nature of dis-
ease in these patients who have previous experience with TNF 
inhibitors. Alternatively, the durability of clinical response to 
golimumab 50 mg may be less than that to golimumab 100 mg 
in this patient population beyond 24 weeks or it could be that 
investigator discretion, rather than objective escalation criteria, 
allowed for the golimumab dose to be escalated despite achieve-
ment of an otherwise acceptable response.
The clinical response observed through week 24 was repro-
duced in the LTE within the placebo group, whereby similar 
ACR20/50/70 response rates were observed after switching to 
golimumab. Moreover, improvements in clinical signs/symp-
toms and physical function observed through week 241 were 
maintained or enhanced through week 100 for most patients 
remaining in the trial. Importantly, 40–45% of patients who 
remained in the study sustained a DAS28-CRP score <3.2 
through week 160. Golimumab dose escalation to 100 mg dur-
ing the LTE increased clinical response rates from before to after 
dose escalation, suggesting that patients who have previous 
experience with TNF inhibitors can beneﬁ t from golimumab 
dose increase(s).
The ability to draw ﬁ rm conclusions from these dose escala-
tion data, however, is limited by several factors, including the 
following: (1) relatively small numbers of patients were avail-
able for analysis at later follow-up visits, (2) the trial was neither 
designed nor powered to compare treatment groups beyond 
week 24 and (3) dose escalation was at the sole discretion of 
investigators. Nonetheless, taken together, the demonstration of 
longer-term efﬁ cacy provides additional support for the week 
24 observation that patients who previously discontinued TNF-
antagonist treatment for any reason respond to golimumab.
Nearly 50% of randomised patients discontinued by week 160, 
which is higher than discontinuation rates observed in other phase 
3 golimumab trials, that is, 23% and 26% in GO-BEFORE and 
GO-FORWARD by week 160 (data not shown). This observation, 
as well as that of unsatisfactory therapeutic effect and AEs being 
common discontinuation reasons, is not surprising given that a 
total of 35% of these patients who have previous experience with 
TNF inhibitors (>65% of whom also have previous experience 
with synthetic DMARD, with ‘synthetic DMARDs’) discontinued 
such prior treatment due to intolerance (63/445 patients) or unsat-
isfactory therapeutic effect (92/445 patients) and thus represent a 
population enriched with patients refractory to and/or intolerant 
of such treatment. Approximately two-thirds of patients contin-
ued pre-existing methotrexate treatment; the remaining patients 
received golimumab monotherapy. The length of the GO-AFTER 
LTE must also be considered when interpreting ﬁ ndings related to 
study agent discontinuation and efﬁ cacy (see above).
The short-term golimumab safety proﬁ le in patients who 
have previous experience with TNF inhibitors was similar to 
that for placebo throughout the 16-week placebo-controlled 
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Table 4 Cumulative summary of golimumab safety through week 160 of the GO-AFTER trial
 
Week 52 golimumab Week 100 golimumab Week 160 golimumab
50 mg 100 mg 50 mg 100 mg 50 mg 100 mg
Number of treated patients* 279 259 279  314 279  330
Average duration of follow-up (weeks)  32.3  36.2  48.3   64.9  59.5  101.6
Average number of injections   7.7   8.7  11.5   15.4  14.1   23.9
Average cumulative dose (mg) 511.4 877.0 575.3 1539.5 705.9 2391.5
Patients with 1 or more AEs 211 (75.6%) 198 (76.4%) 223 (79.9%)  259 (82.5%) 226 (81.0%)  296 (89.7%)
Common AEs†
 Upper respiratory tract infection  30 (10.8%)  42 (16.2%)  43 (15.4%)   55 (17.5%)  44 (15.8%)   68 (20.6%)
 RA  30 (10.8%)  20 (7.7%)  34 (12.2%)   37 (11.8%)  39 (14.0%)   53 (16.1%)
 Nasopharyngitis  22 (7.9%)  28 (10.8%)  26 (9.3%)   36 (11.5%)  27 (9.7%)   45 (13.6%)
 Sinusitis  21 (7.5%)  17 (6.6%)  26 (9.3%)   30 (9.6%)  28 (10.0%)   41 (12.4%)
 Diarrhoea  15 (5.4%)  19 (7.3%)  16 (5.7%)   27 (8.6%)  17 (6.1%)   35 (10.6%)
Death‡
 Observed number of patients   0 (0.0%)   0 (0.0%)   0 (0.0%)    0 (0.0%)   0 (0.0%)    4 (1.2%)
 Incidence (95% CI) per 100 pt-yrs    0.00 
(0.00 to 0.94)
    0.62 
(0.17 to 1.59)
Discontinuation due to AE(s)  18 (6.5%)   8 (3.1%)  23 (8.2%)   16 (5.1%)  25 (9.0%)   38 (11.5%)
Serious AEs  36 (12.9%)  20 (7.7%)  45 (16.1%)   52 (16.6%)  49 (17.6%)   83 (25.2%)
Common serious AEs§
 Pneumonia   4 (1.4%)   2 (0.8%)   5 (1.8%)    4 (1.3%)   5 (1.8%)    8 (2.4%)
 RA   4 (1.4%)   0 (0.0%)   6 (2.2%)    3 (1.0%)   6 (2.2%)    7 (2.1%)
 Osteoarthritis   3 (1.1%)   0 (0.0%)   4 (1.4%)    4 (1.3%)   4 (1.4%)    5 (1.5%)
 Arthralgia   1 (0.4%)   1 (0.4%)   1 (0.4%)    3 (1.0%)   1 (0.4%)    3 (0.9%)
 Infections 118 (42.3%) 122 (47.1%) 140 (50.2%)  176 (56.1%) 149 (53.4%)  205 (62.1%)
Serious infections¶
 Observed number of patients  10 (3.6%)   8 (3.1%)  14 (5.0%)   18 (5.7%)  14 (5.0%)   30 (9.1%)
 Observed number of serious infections  10  11  15   26  15   52
 Incidence (95% CI) per100 pt-yrs    5.78 
(2.77 to 10.63)
   6.10 
(3.05 to 10.92)
   5.79 
(3.24 to 9.95)
    6.63 
(4.33 to 9.72)
   4.70 
(2.63 to 7.75)
    8.07 
(6.02 to 10.58)
Common serious infections**
 Pneumonia   4 (1.4%)   2 (0.8%)   5 (1.8%)    4 (1.3%)   5 (1.8%)    8 (2.4%)
 Urinary tract infection   2 (0.7%)   0 (0.0%)   2 (0.7%)    2 (0.6%)   2 (0.7%)    3 (0.9%)
 Sepsis   0 (0.0%)   1 (0.4%)   0 (0.0%)    2 (0.6%)   0 (0.0%)    4 (1.2%)
 Diverticulitis   0 (0.0%)   1 (0.4%)   0 (0.0%)    2 (0.6%)   0 (0.0%)    3 (0.9%)
 Abdominal abscess   0 (0.0%)   0 (0.0%)   0 (0.0%)    0 (0.0%)   0 (0.0%)    2 (0.6%)
 Cellulitis   0 (0.0%)   0 (0.0%)   1 (0.4%)    1 (0.3%)   1 (0.4%)    1 (0.3%)
 Gastroenteritis   1 (0.4%)   2 (0.8%)   0 (0.0%)    2 (0.6%)   0 (0.0%)    2 (0.6%)
 Herpes zoster   0 (0.0%)   0 (0.0%)   0 (0.0%)    0 (0.0%)   0 (0.0%)    2 (0.6%)
 Infection   0 (0.0%)   0 (0.0%)   0 (0.0%)    1 (0.3%)   0 (0.0%)     2 (0.6%)
 Urosepsis   2 (0.7%)   0 (0.0%)   2 (0.7%)    0 (0.0%)   2 (0.7%)    0 (0.0%)
All malignancies‡
 Observed number of patients   1   2   2    3   3   13
 Incidence (95% CI) per 100 pt-yrs   0.58 (0.01 to 3.24)   1.12 (0.14 to 4.03)   0.77 (0.09 to 2.80)    0.77 (0.16 to 2.24)  0.95 (0.20 to 2.77)    2.04 (1.09 to 3.49)
Lymphoma
 Observed number of patients   0   1   0    1   0    4
 Incidence (95% CI) per 100 pt-yrs   0.00 (0.00 to 1.74)   0.56 (0.01 to 3.11)   0.00 (0.00 to 1.16)    0.26 (0.01 to 1.42)  0.00 (0.00 to 0.94)    0.62 (0.17 to 1.59)
Nonmelanoma skin cancers
 Observed number of patients   1   0   1    1   1    5
 Incidence (95% CI) per 100 pt-yrs   0.58 (0.01 to 3.24)   0.00 (0.00 to 1.67)   0.39 (0.01 to 2.16)    0.26 (0.01 to 1.42)  0.31 (0.01 to 1.75)    0.78 (0.25 to 1.82)
Other malignancies‡
 Observed number of patients  0   1   1    1   2    4
 Incidence (95% CI) per 100 pt-yrs  0.00 (0.00 to 1.74)   0.56 (0.01 to 3.11)   0.39 (0.01 to 2.15)    0.26 (0.01 to 1.42)  0.63 (0.08 to 2.27)    0.62 (0.17 to 1.59)
Golimumab injection-site reactions
 Patients  20 (7.2%)  23 (8.9%)  20 (7.2%)   30 (9.6%)  21 (7.5%)   31 (9.4%)
 Injections  26/2157 (1.2%)  51/2260 (2.3%)  29/3210 (0.9%)   73/4835 (1.5%)  30/3939 (0.8%)   82/7893 (1.0%)
Data presented are number (%) of patients unless noted otherwise noted.
*Patients could appear in more than one column.
†Occurring in ≥10% of patients in either golimumab dose group.
‡As previously reported by Smolen and colleagues,1 an additional patient in the placebo group who did not meet the early escape criteria died of pancreatic cancer. The resulting 
incidence is 1.73 (95% CI 0.04 to 9.65) and 1.73 (95% CI 0.04 to 9.66) per 100 pt-yrs of follow-up for death and other/all malignancies, respectively.
§Occurring in ≥1% of patients in either golimumab dose group.
¶Serious infections were observed in 5 (3.2%) patients through a total of 58 pt-years of follow-up pertaining to receipt of placebo, equating to an incidence of 8.66 (95% CI 28.1 to 
20.22) per 100 pt-yrs of follow-up.
**Occurring in ≥2 patients overall.
AE, adverse event; pt-years, patient-years of follow-up; RA, rheumatoid arthritis.
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period.1 Through week 160, the length of follow-up for the pla-
cebo-controlled phase was 16 weeks versus 60 and 102 weeks 
for golimumab 50 mg and 100 mg, respectively. Thus, the higher 
incidences observed for speciﬁ c AE categories through week 
160 (table 4) relative to observations through week 161 were 
not unexpected given follow-up periods almost 4 times (50 mg) 
and more than 6 times (100 mg) the length of placebo-controlled 
follow-up. Also through week 160, patients treated with goli-
mumab 100 mg received an average cumulative dose >3 times 
that for golimumab 50 mg (table 4), yielding an overall follow-up 
of golimumab 100 mg (645 pt-years) ~10 times that for placebo 
(58 pt-years) and 2 times that for golimumab 50 mg (319 pt-yrs). 
These imbalances in exposure/follow-up were largely driven by 
the fact that, while 33% of enrolled patients were randomised 
to golimumab 100 mg, by week 160, 81% of the remaining 
patients were receiving golimumab 100 mg. When adjusted for 
length of patient follow-up, however, the incidences of serious 
infection, malignancy/lymphoma and death were higher in the 
100 mg group, indicating a potential effect of golimumab dose. 
A similar pattern of a higher incidence of certain AEs with higher 
drug exposure was observed in the START trial of inﬂ iximab in 
patients with RA. In that trial, high serum inﬂ iximab concentra-
tions during the induction regimen of 10 mg/kg given at weeks 
0, 2 and 6 may have been associated with an increased risk of 
serious infections during the ﬁ rst 22 weeks of the trial. During 
the maintenance period, when infusions were administered 
every 8 weeks and peak serum inﬂ iximab concentrations may 
not have reached the same level as they did during the induction 
period, the risk of serious infection was reduced and consistent 
with that observed with lower inﬂ iximab doses.14
B cell lymphomas were the most common of lymphoma cases 
(supplementary table 1), which is consistent with that observed 
in patients with RA.15 Irrespective of TNF-antagonist treatment, 
patients with RA have an increased lymphoma risk versus the 
general population;16 this risk increases with disease duration 
and severity.15 17–19 GO-AFTER patients, with average disease 
durations of 10.6–12.4 years and previous receipt of anti-TNF 
treatment (indicating active refractory disease), represent an RA 
cohort consistent with increased lymphoma risk.15
The potential contribution of anti-TNF treatment to lym-
phoma remains an area of debate. Although an increased risk 
has been suggested with anti-TNF treatment,20 an alternative 
hypothesis asserts that lymphoma risk is actually related to RA 
severity and may decrease with control of chronic inﬂ amma-
tion via disease-modifying treatment.18 21 Consistent with this 
hypothesis, Askling and colleagues22 observed no overall eleva-
tion of cancer risk and no increase with increasing duration of 
anti-TNF treatment in their evaluation of 6366 patients with RA 
(25 693 pt-years of follow-up). Data supporting the possible rela-
tionship between clinical status and lymphoma have also been 
reported by Wolfe and Michaud in their prospective evaluation 
of 19 562 patients (89 710 pt-years) enrolled in a longitudinal RA 
registry.23 24 However, because patients with the worst clinical 
status appeared to receive anti-TNF treatment preferentially, the 
authors were limited in their ability to establish causal relation-
ships between RA treatment and lymphoma.23 24
At baseline, the four GO-AFTER patients diagnosed as having 
lymphoma had disease durations ranging from 5 to 31 years and 
substantial tender/swollen joint counts; three of the four patients 
also had baseline DAS28 and/or SDAI scores falling within the 
Table 5 Number of patients with one or more malignancies through week 160 compared with the expected number of malignancies from the general 
US population according to the SEER database
 Placebo*
Golimumab†
50 mg 100 mg Combined
Treated patients in the study‡§ 155 279 328 431
Type of malignancy¶
Lymphoma
 Patient-years of follow-up
 Total  58 302 560 863
 Median   0.3   0.8   1.7   2.4
 Observed/expected** number of patients with event   0/0.02   0/0.11   4/0.20   4/0.30
 SIR†† (95% CI‡‡)   0.00 (0.00 to 149.04)   0.00 (0.00 to 28.04)  20.37 (5.55 to 52.15)   13.19 (3.59 to 33.78)
Other malignancies
 Patient-years of follow-up
 Total  57 302 560 863
 Median   0.3   0.8   1.7  2.4
 Observed/expected** number of patients with event   1/0.45   2/2.44   2/4.40   4/6.84
 SIR†† (95% CI‡‡)   2.24 (0.06 to 12.50)   0.82 (0.10 to 2.96)   0.45 (0.06 to 1.64)   0.58 (0.16 to 1.50)
All malignancies
 Patient-years of follow-up
 Total  57 302 560 862
 Median   0.3   0.8   1.7   2.4
 Observed/expected** number of patients with event   1/0.46   2/2.54   6/4.58   8/7.12
 SIR†† (95% CI‡‡)   2.15 (0.05 to 12.00)   0.79 (0.10 to 2.84)   1.31 (0.48 to 2.85)   1.12 (0.49 to 2.21)
*Received placebo with or without MTX.
†Received golimumab with or without MTX. Subcutaneous injections were administered every 4 weeks.
‡Patients may appear in more than one column.
§Through 12 August 2009.
¶Includes patients with malignancies (excluding nonmelanoma skin cancers, which are not included in the SEER database) during the study.
**The expected number of patients with malignancies is based on the SEER database,13 adjusted for age, gender and race.
††SIR is the observed number of patients with malignancy divided by expected number of patients with malignancy.
‡‡CI based on an exact method.
MTX, methotrexate; SEER, Surveillance, Epidemiology and End Results (database); SIR, standardised incidence ratio.
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higher quartiles of scores observed across all patients, and fol-
low-up scores at the time of lymphoma diagnosis were largely 
consistent with those documented at baseline, with the excep-
tion of one patient whose DAS28 and SDAI scores improved 
from a higher to a lower quartile from baseline to that time. 
Further discussion of these four patients with lymphoma is pro-
vided as online supplemental text.
In addition to the study limitations discussed above, the ability 
to evaluate effects of golimumab dose on safety was also limited 
by the GO-AFTER study design that allowed for dose escalation 
and yielded markedly differing lengths of follow-up for goli-
mumab 50 mg (319 pt-years) versus 100 mg (645 pt-years).
Taken together with ﬁ ndings previously reported through week 
24 of the GO-AFTER trial,1 these longer-term ﬁ ndings through 3 
years support the efﬁ cacy of golimumab in patients with active 
RA previously treated with TNF antagonist(s); deﬁ nitive conclu-
sions regarding long-term safety will require further monitoring.
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